[1] VELAMOOR V R. Neuroleptic malignant syndrome. Recognition, prevention and management[J]. Drug Saf, 1998, 19(1): 73-82.
[2] VELAMOOR V R, NORMAN R M, CAROFF S N, et al. Progression of symptoms in neuroleptic malignant syndrome[J]. J Nerv Ment Dis, 1994, 182(3): 168-173.
[3] VELAMOOR R. Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management[J]. Asian J Psychiatr, 2017, 29: 106-109.
[4] CAROFF S N, MANN S C. Neuroleptic malignant syndrome[J]. Med Clin North Am, 1994, 77(1):185-202.
[5] SAKKAS P, DAVIS J M, JANUCAK P G, et al. Drug treatment of the neuroleptic malignant syndrome[J]. Psychopharmacol Bull, 1991, 27 (3): 381-384.
[6] PATIL S P, SUBRAMANYAM A A, KAMATH R M, et al. Low serum iron as a possible risk factor for neuroleptic malignant syndrome[J]. Int J Appl Basic Med Res, 2014, 4 (2):117-118.
[7] CHOPRA M P, PRAKASH S S, RAGURAM R. The neuroleptic malignant syndrome: anIndian experience[J]. Compr Psychiatry, 1999, 40 (1):19-23.
[8] SEITZ D P, GILL S S. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature[J]. Psychomatics, 2009, 50 (1):8-15.
[9] CAROFF S N, MANN S C, CAMPBELL E C. Atypical antipsychotics and neuroleptic malignant syndrome[J]. Psychiatr Ann, 2000, 30 (5):314-321. |
